Cooper Companies (NASDAQ:COO) Director Paul Keel Buys 4,701 Shares

The Cooper Companies, Inc. (NASDAQ:COO) Director Paul Keel bought 4,701 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was bought at an average cost of $53.18 per share, for a total transaction of $249,999.18. Following the completion of the transaction, the director directly owned 4,701 shares in the company, valued at approximately $249,999.18. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Cooper Companies Stock Performance

COO traded down $0.95 on Tuesday, reaching $53.27. The company had a trading volume of 4,408,999 shares, compared to its average volume of 2,501,526. The Cooper Companies, Inc. has a 1 year low of $51.01 and a 1 year high of $89.83. The stock has a market capitalization of $10.13 billion, a PE ratio of 18.18, a P/E/G ratio of 2.19 and a beta of 0.82. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23. The stock has a 50-day moving average price of $71.25 and a 200-day moving average price of $69.40.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. Cooper Companies’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, research analysts forecast that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies announced that its board has authorized a stock buyback plan on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Hedge Funds Weigh In On Cooper Companies

Several institutional investors have recently added to or reduced their stakes in COO. New York Life Investment Management LLC grew its stake in shares of Cooper Companies by 0.6% in the 4th quarter. New York Life Investment Management LLC now owns 27,344 shares of the medical device company’s stock valued at $2,241,000 after purchasing an additional 158 shares during the last quarter. Root Financial Partners LLC increased its holdings in shares of Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 162 shares during the period. Essential Partners LLC raised its stake in shares of Cooper Companies by 23.4% during the first quarter. Essential Partners LLC now owns 874 shares of the medical device company’s stock worth $62,000 after purchasing an additional 166 shares during the last quarter. Allworth Financial LP raised its stake in shares of Cooper Companies by 14.1% during the fourth quarter. Allworth Financial LP now owns 1,355 shares of the medical device company’s stock worth $111,000 after purchasing an additional 167 shares during the last quarter. Finally, SJS Investment Consulting Inc. lifted its holdings in shares of Cooper Companies by 107.5% during the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after purchasing an additional 187 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Zacks Research downgraded Cooper Companies from a “hold” rating to a “strong sell” rating in a research note on Friday. BNP Paribas Exane decreased their price objective on Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a report on Monday, June 8th. Robert W. Baird set a $61.00 price objective on Cooper Companies and gave the company a “neutral” rating in a report on Thursday, September 10th. Wall Street Zen lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Cooper Companies in a report on Friday, September 4th. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $71.47.

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.